CD28 is a pivotal T-cell molecular the plays important roles in T-cell activation, HIV pathogenesis, and the induction and maintenance of peripheral tolerance and autoimmunity. The overall objective of this proposal is to investigate the CD28 signal transduction mechanisms during human T-lymphocyte activation. Recent evidence strongly indicates that both JNK1 (the c-Jun N-terminal kinase) and the Rel/NF-kappaB transcription factors/oncoproteins are involved in the IL-2/HIV gene activation by CD28 signaling. To date, JNK1 is the only kinase known to be activated exclusively by TCR/CD3 plus CD28 costimulation but not by TCR/CD3 signaling alone. The purpose of this study will be; (i) to examine the potential modifications of RelA/cRel or lkappaBalpha by JNK1, and (ii) to define additional transcription factors or enzymes that are upstream or downstream of jNK1 in the CD28 signaling pathway.
The specific aims are as follows: 1. Roles of JNK1 Kinase in CD28 Signaling Pathway. We will test our hypothesis to determine if JNK1 directly or indirectly phosphorylates lkappa Balpha or RelA/cRel which leads to nuclear translocation or functional activation of RelA/cRel, and subsequently activation of IL-2/HIV gene transcription via the CD28RE/kappaB enhancer. The experiments will include protein interaction assays, kinase assays, transfections, and site- directed mutagenesis. 2. Cloning of Novel JNK1-interacting Proteins. We will isolate the human cDNAs encoding novel transcription factors or kinases that interact with JNK1 kinase using the yeast two-hybrid system. The experiments will include library screening, isolation/cloning of full-length cDNAs, antibody production, and in vivo protein interaction assays. 3. Biochemical and Functional Characterizations of Novel JNK1-interacting proteins (JIPs). We will further characterize the novel JIPs cloned in AIM 2. We expect the JIPs will fall into the following categories; (i) transcription factors that are the targets/substrates of JNK1, (ii) kinases that are the targets/substrates of JNK1, (iii) kinases that are upstream of JNK1, (iv) phosphatases that are upstream of JNK1, and (v) other JNK1- binding proteins. Various biochemical and functional assays, as described in AIM-1, will be used to define the functions of the JIPs. These studies will provide fundamental understanding about (i) the distal signaling events during CD28 signal transduction, (ii) the molecular mechanisms of gene regulation/oncogenesis mediated by Rel/NF kappaB proteins, and (iii) the actions of JNK1 in the emerging/novel stress- activated signaling pathway. An understanding of the CD28-mediated activation of Rel/NF-kappaB functions should also provide insight about the interplay between CD28 signaling and HIV-1 gene regulation/replication in HIV-1 pathogenesis. Finally, the information gained in these studies will be of value in the future design of therapeutic agents for immunological disorders including autoimmunity, graft rejection and AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI038649-03
Application #
2442671
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1995-07-01
Project End
2000-06-30
Budget Start
1997-07-01
Budget End
1998-06-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhou, Guisheng; Mihindukulasuriya, Kathie A; MacCorkle-Chosnek, Rebecca A et al. (2002) Protein phosphatase 4 is involved in tumor necrosis factor-alpha-induced activation of c-Jun N-terminal kinase. J Biol Chem 277:6391-8
Ling, P; Meyer, C F; Redmond, L P et al. (2001) Involvement of hematopoietic progenitor kinase 1 in T cell receptor signaling. J Biol Chem 276:18908-14
Ma, W; Xia, C; Ling, P et al. (2001) Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes. Oncogene 20:1703-14
MacCorkle-Chosnek, R A; VanHooser, A; Goodrich, D W et al. (2001) Cell cycle regulation of c-Jun N-terminal kinase activity at the centrosomes. Biochem Biophys Res Commun 289:173-80
Chen, Y R; Shrivastava, A; Tan, T H (2001) Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate. Oncogene 20:367-74
Chen, Y R; Tan, T H (2000) The c-Jun N-terminal kinase pathway and apoptotic signaling (review). Int J Oncol 16:651-62
Yu, R; Mandlekar, S; Tan, T H et al. (2000) Activation of p38 and c-Jun N-terminal kinase pathways and induction of apoptosis by chelerythrine do not require inhibition of protein kinase C. J Biol Chem 275:9612-9
Yu, R; Mandlekar, S; Lei, W et al. (2000) p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem 275:2322-7
Yu, R; Chen, C; Mo, Y Y et al. (2000) Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J Biol Chem 275:39907-13
Tchou, W W; Yie, T A; Tan, T H et al. (1999) Role of c-Jun N-terminal kinase 1 (JNK1) in cell cycle checkpoint activated by the protease inhibitor N-acetyl-leucinyl-leucinyl-norleucinal. Oncogene 18:6974-80

Showing the most recent 10 out of 27 publications